Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma

Biochemical and Biophysical Research Communications

Volumn 421, Issue 4, 2012, Pages 837-843

  Nomura, Fumio ^a   Sogawa, Kazuyuki ^a   Noda, Kenta ^a   Seimiya, Masanori ^a   Matsushita, Kazuyuki ^a   Miura, Toshihide ^a   Tomonaga, Takeshi ^b   Yoshitomi, Hideyuki ^c   Imazeki, Fumio ^c   Takizawa, Hirotaka ^d   Mogushi, Kaoru ^e   Miyazaki, Masaru ^c   Yokosuka, Osamu ^c  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d Kashiwado Clinic in Port Square of the Kashiwado Memorial Foundation   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

AFP; Autoantibody; DCP; HCC; Ku86; PIVKA II

Indexed keywords

ALPHA FETOPROTEIN; ANTIVITAMIN K; AUTOANTIBODY; BIOLOGICAL MARKER; KU86 ANTIBODY; NUCLEAR PROTEIN; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; SOLID TUMOR; TUMOR; VIRUS DETECTION;

AGED; ANTIGENS, NUCLEAR; AUTOANTIBODIES; CARCINOMA, HEPATOCELLULAR; DNA-BINDING PROTEINS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

HEPATITIS C VIRUS;

EID: 84861223639     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.099     Document Type: Article

References (31)

1. Bosch F.X., Ribes J., Cléries R., et al. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 2005, 9:191-211.
2. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992, 15:948-963.
3. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
4. Okita K. Clinical aspects of hepatocellular carcinoma in Japan. Intern. Med. 2006, 45:229-233.
5. McMahon B.J., Bulkow L., Harpster A., et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000, 32:842-846.
6. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004, 130:417-422.
7. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 55:1020-1022.
8. Takayasu K., Muramatsu Y., Mizuguchi Y., et al. Imaging of early hepatocellular carcinoma and adenomatous hyperplasia (dysplastic nodules) with dynamic ct and a combination of CT and angiography: experience with resected liver specimens. Intervirology 2004, 47:199-208.
9. Frericks B.B., Loddenkemper C., Huppertz A., et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. Am. J. Roentgenol. 2009, 193:1053-1060.
10. Nomura F., Ohnishi K., Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989, 64:1700-1707.
11. Sherman M., Peltekian K.M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995, 22:432-438.
12. Lok A.S., Sterling R.K., Everhart J.E., et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010, 138:493-502.
13. Aoyagi Y., Saitoh A., Suzuki Y. Fucosylation index of alpha-fetoprotein, a possible aid in the early recognition of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1993, 17:50-52.
14. Tsai S.L., Huang G.T., Yang P.M., et al. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990, 11:481-488.
15. Nomura F., Ishijima M., Kuwa K., et al. Serum des-gamma-carboxyprothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am. J. Gastroenterol. 1999, 94:650-654.
16. Nakatsura T., Yoshitake Y., Senju S., et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem. Biophys. Res. Commun. 2003, 306:16-25.
17. Spangenberg H.C., Thimme R., Blum H.E. Serum markers of hepatocellular carcinoma. Semin. Liver Dis. 2006, 26:385-390.
18. Malaguarnera G., Giordano M., Paladina I., et al. Serum markers of hepatocellular carcinoma. Dig. Dis. Sci. 2010, 55:2744-2755.
19. Feng J.T., Shang S., Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene 2006, 25:3810-3817.
20. Lin Y., Dynan W.S., Lee J.R., et al. The current state of proteomics in GI oncology. Dig. Dis. Sci 2009, 54:431-457.
21. Caron M., Choquet-Kastylevsky G., Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol. Cell. Proteomics 2007, 6:1115-1122.
22. Tan H.T., Low J., Lim S.G., et al. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009, 276:6880-6904.
23. Seimiya M., Tomonaga T., Matsushita K., et al. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology 2008, 48:519-530.
24. Suzuki H., Graziano D.F., McKolanis J., et al. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin. Cancer Res. 2005, 11:1521-1526.
25. Hortin G.L. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 2006, 52:1223-1237.
26. Nakagawa T., Takeishi S., Kameyama A., et al. Glycomic analyses of glycoproteins in bile and serum during rat hepatocarcinogenesis. J. Proteome Res. 2010, 9:4888-4896.
27. B. Adamczyk, T. Tharmalingam, P.M. Rudd, Glycans as cancer biomarkers, Biochim. Biophys. Acta (2011) [Epub ahead of print].
28. Mimori T., Hardin J.A., Steiz J.A. Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. J. Biol. Chem. 1986, 261:2274-2278.
29. Smith G.C.M., Jackson S.P. The DNA-dependent protein kinase. Gene. Dev. 1999, 13:916-934.
30. Luk J.M., Su Y.C.F., Lam S.C.T., et al. Proteomic identification of Ku70/Ku80 autoantigen recognized by monoclonal antibody against hepatocellular carcinoma. Proteomics 2005, 5:1980-1986.
31. Prabhakar B.S., PAllaway G., Srinvasappa J., et al. Cell surface expression of the 70kD component of Ku, a DNA-binding nuclear autoantigen. J. Clin. Invest. 1990, 86:1301-1305.